Received Mar 3, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 1 | Z005718 | — |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 2 | Z005718 | — |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | — | — |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | — | — |
No adverse effects reported; patient received early dose of MMR II. First dose was given on 11/5/2025 and second dose given on 11/21/2025.; This spontaneous report was received from an Office Manager and refers to a 15-month-old patient of unknown gender. The patient's concurrent conditions, medical history, previous drug reactions, drug allergies and concomitant therapies were not reported. On 05-Nov-2025 and 21-Nov-2025, the patient was vaccinated with the first and second doses (respectively) of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), Solution for injection (Both doses with lot # Z005718 has been verified to be valid, expiration date: 07-Mar-2027) (route of administration and site of administration were not provided) which were reconstituted in sterile diluents (strength, route of administration, site of administration, lot #, and expiration date were not provided) as prophylaxis (Inappropriate schedule of product administration). Unclear if second dose was due to outbreak. No adverse effects reported.